XTENT to Present CUSTOM I and CUSTOM II Trial Data a...(of Cardiology at the HELIOS Heart Cen...),Health

Center in Siebgurg, Germany and principal investigator of the CUSTOM I and

II clinical trials, will review the results to date from Biolimus A9(R)

DES clinical trials and registries. Professor Grube will present two-year

results from the CUSTOM I clinical trial and one-year results from the

CUSTOM II clinical trial.

Bernard de Bruyne, M.D. Ph.D, Cardiovascular Center, OLV Hospital in

Aalst, Belgium, will provide an overview of the Custom NX technology in a

presentation titled "XTENT Custom NX DES Systems: A Novel Approach to the

Percutaneous Treatment of Coronary Artery Disease (CAD)."

Time/Location: 8:00-10:00 p.m. EDT; Renaissance Washington, D.C. Hotel,

Grand Ballroom, 999 Ninth Street NW

Monday, October 22

Event: Analyst Webcast and Teleconference on CUSTOM I and CUSTOM II Data

XTENT will host a webcast and teleconference call to review the CUSTOM I

and CUSTOM II data presented on Sunday. The teleconference and slide

presentation can be accessed via the investor relations section of the

company's website at http://investor.xtentinc.com/events.cfm or by calling

888-663-2258 (from the U.S.), 913-312-1277 (international). Please dial in

or access the website five to ten minutes prior to the beginning of the

call. The webcast will be archived on the website for a minimum of three

months, and can be accessed at the investor relations portion of the

company's website at http://investor.xtentinc.com

Time/Location: 7:00 a.m. EDT

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of
'/>"/>